Abstract
Mycobacteria are members of the Actinomycetales order, and they are classified into one family, Mycobacteriaceae. More than 20 mycobacterial species cause disease in humans. The Mycobacterium group, called the Mycobacterium tuberculosis complex (MTBC), has nine closely related species that cause tuberculosis in animals and humans. TB can be detected worldwide and one-fourth of the world’s population is contaminated with tuberculosis. According to the WHO, about two million dies from it, and more than nine million people are newly infected with TB each year. Mycobacterium tuberculosis (M. tuberculosis) is the most potential causative agent of tuberculosis and prompts enormous mortality and morbidity worldwide due to the incompletely understood pathogenesis of human tuberculosis. Moreover, modern diagnostic approaches for human tuberculosis are inefficient and have many lacks, while MTBC species can modulate host immune response and escape host immune attacks to sustain in the human body. “Multi-omics” strategies such as genomics, transcriptomics, proteomics, metabolomics, and deep sequencing technologies could be a comprehensive strategy to investigate the pathogenesis of mycobacterial species in humans and offer significant discovery to find out biomarkers at the early stage of disease in the host. Thus, in this review, we attempt to understand an overview of the mission of “omics” approaches in mycobacterial pathogenesis, including tuberculosis, leprosy, and other mycobacterial diseases.
Highlights
Mycobacterial disease such as tuberculosis (TB) continues to be one of the world’s leading infectious diseases, claiming over 1.5 million lives annually or 4000 lives each day, and the Global TB Report 2020 predicts that 10 million new cases and 1.4 million fatalities occurred in 2019 (Chakaya et al, 2021; Parvez, 2022)
This review focused on current mycobacterial omics technologies and their application to determining mycobacterial signatures during the disease’s early stages
Current multi-omics techniques suggest that leveraging the host response to detect mycobacterial diseases like TB and leprosy may be feasible despite the ineffectiveness of prior diagnostics
Summary
Mycobacterial disease such as tuberculosis (TB) continues to be one of the world’s leading infectious diseases, claiming over 1.5 million lives annually or 4000 lives each day, and the Global TB Report 2020 predicts that 10 million new cases and 1.4 million fatalities occurred in 2019 (Chakaya et al, 2021; Parvez, 2022). In this complete review article, the use of multi-omics techniques, such as genomics (DNA), transcriptomics (mRNA), proteomics (proteins), metabolomics (metabolites), and lipidomics (lipids), will be discussed as a framework for developing biomarkers for mycobacterium disease. Research advancing related to genomics, transcriptomics, proteomics, metabolomics, lipidomics, glycomics, and glycoproteomics provide additional pathways for investigating the fundamental biology of Mtb infection.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have